Natera Inc., a leading innovator in prenatal genetic testing, today announced the appointment of Herman “Herm” Rosenman to the position of chief financial officer. Mr. Rosenman has served as a member of the company’s board of directors since 2013 and brings more than 30 years of public company operating and financial experience to Natera. He will join the company on Feb. 10, 2014.<br /><br />Mr. Rosenman was most recently the senior vice president of finance and chief financial officer of Gen-Probe Inc., where he was instrumental in its September 2002 IPO and its August 2012 sale to Hologic Inc. for $3.7 billion. Prior to joining Gen-Probe, he was president and chief executive officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, and president and chief executive officer of RadNet Management Inc., a large healthcare provider. At RadNet, he developed and implemented strategies that resulted in the company’s successful turnaround. Before this, he was the chief financial officer of Rexene Corp., a Fortune 1000 company in the petrochemicals industry, where he led its successful $150 million IPO and $500 million debt financing. Prior to Rexene, Mr. Rosenman was a partner at Coopers & Lybrand (now PricewaterhouseCoopers LLP), where he served numerous Fortune 1000 clients, principally in the pharmaceuticals and telecommunications industries.<br /><br />“This is a big win for Natera,” said Matthew Rabinowitz, Ph.D., chief executive officer of Natera. “Herm has been a member of our Board of Directors and now will play a key role in the continued expansion of our company.”<br /><br />Mr. Rosenman currently serves as chairman of the audit committees of Oxford Immunotec Ltd., Medistem Inc. and VIVUS Inc., where he is also a member of their compensation committees. In addition, he is a member of the advisory board for Scripps Clinics/Green Hospital in San Diego. A C.P.A., Mr. Rosenman received a B.B.A. in finance and accounting from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.<br /><br />“I look forward to working as part of the Natera team to support the company’s continued growth and deliver the most accurate reproductive genetic testing in the world,” Mr. Rosenman said.<br /><br />About Natera<br /><br />Natera Inc. is a genetic testing company that specializes in analyzing tiny quantities of DNA for reproductive health. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to analyze fetal chromosomes and understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera's PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. These tests were developed by Natera, a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). In August, Natera was selected by the World Economic Forum as a Technology Pioneer for innovations in prenatal care. For more information, visit www.natera.com.